AEGiS-FDA: HHS/FDA Tentatively Approves Another First-Time Generic AIDS Drug Associated with the President's Emergency Plan for AIDS Relief

Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

HHS/FDA Tentatively Approves Another First-Time Generic AIDS Drug Associated with the President's Emergency Plan for AIDS Relief

Food and Drug Administration - July 13, 2005

The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS/FDA) today announced the tentative approval of zidovudine tablets manufactured by Ranbaxy Laboratories Limited of Guragon, India. This product contains 300 mg of zidovudine in each tablet, and is the first generic version of the already-approved Retrovir brand of the product manufactured by GlaxoSmithKline. Because of the tentative approval by HHS/FDA, this Ranbaxy generic product will now be available for consideration for purchase and use outside the United States under the President's Emergency Plan for AIDS Relief.

"This action today by HHS/FDA adds yet another valuable product to the growing list of effective and safe quality medicines available for consideration for purchase under the President's Emergency Plan," said Murray M. Lumpkin, M.D., Acting Deputy Commissioner (International and Special Programs) at the FDA. "We are especially appreciative of HHS/FDA's Office of Generic Drugs for the exceptional work they continue to do to help assure that patients this program serves receive medications they can trust and that can indeed help improve the quality of their lives."

The Emergency Plan for AIDS Relief, which President Bush first announced in his 2003 State of the Union Address, is currently providing $15 billion to fight the HIV/AIDS pandemic over five years, with a special focus on 15 of the hardest-hit countries. The President's Emergency Plan is designed to prevent seven million new HIV infections, treat at least two million HIV-infected people, and care for ten million HIV-affected individuals, AIDS orphans and vulnerable children. It targets three specific areas related to HIV/AIDS:

* Prevention of HIV transmission;

* Treatment of AIDS and associated conditions;

* Care, including palliative care for HIV infected-individuals, and care for orphans and vulnerable children.

Zidovudine is in the class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), which help keep the AIDS virus from reproducing. This anti-retroviral drug is intended to be used with other anti-retroviral agents for the treatment of HIV-1 infection.

The agency's tentative approval means that although existing patents and/or exclusivity prevent marketing of this product in the United States, it meets all of HHS/FDA's quality, safety and efficacy standards for U.S. marketing. More information on HIV and AIDS is available online at HHS/FDA's website: http://www.fda.gov/oashi/aids/hiv.html.

050713
FD050703

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .